These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33364840)

  • 1. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
    Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
    Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
    Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Wu B; Shi L
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's Perspective.
    Mirzayeh Fashami F; Levine M; Xie F; Blackhouse G; Tarride JE
    Curr Oncol; 2023 May; 30(5):4688-4699. PubMed ID: 37232812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
    Shu Y; Liu Y; He X; Ding Y; Zhang Q
    Front Pharmacol; 2022; 13():818579. PubMed ID: 36034834
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.
    Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB
    JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
    Zhu Y; Liu K; Cao H; Zhu H
    J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
    Teppala S; Scuffham PA; Tuffaha H
    Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
    Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
    J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
    Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
    Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
    PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    Leung JH; Lang HC; Wang SY; Lo HF; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):489-496. PubMed ID: 34241562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
    Nie J; Wu H; Sun L; Ding Y; Luan Y; Wu J
    Front Pharmacol; 2022; 13():987337. PubMed ID: 36686677
    [No Abstract]   [Full Text] [Related]  

  • 20. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
    Zhu Y; Yang Q; Liu K; Cao H; Zhu H
    J Gynecol Oncol; 2024 Jan; 35(1):e2. PubMed ID: 37477106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.